Abstract
Actinomycin D is an anti-cancer drug commonly used in the treatment of paediatric malignancies such as Wilms’ tumour,
Ewing’s sarcoma and rhabdomyosarcoma. Despite its long history of clinical use, little is known about the pharmacokinetics of
actinomycin D in humans, largely due to problems in developing an analytical assay with the required sensitivity to measure
relevant clinical concentrations.